<DOC>
	<DOCNO>NCT00039546</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know chemotherapy regimen effective treat woman surgery breast cancer . PURPOSE : Randomized phase III trial compare effectiveness paclitaxel , epirubicin , cyclophosphamide without gemcitabine treat woman undergone surgery breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Women With Breast Cancer Who Have Undergone Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Compare 5-year 10-year disease-free survival overall survival woman completely resect early stage breast cancer treat adjuvant paclitaxel , epirubicin , cyclophosphamide without gemcitabine . - Compare toxicity , dose-intensity , tolerability regimens patient . - Compare serious adverse event patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord nodal status ( negative v 1-3 v 4 ) , age ( 50 vs 50 ) , estrogen receptor status ( negative v weakly positive v positive ) , concurrent radiotherapy ( vs yes ) , HER2 status ( 3+ overexpression v v measure ) , country . Patients randomize 1 2 treatment arm . - Arm I : Patients receive epirubicin IV , cyclophosphamide IV , paclitaxel IV 3 hour day 1 . Patients also receive gemcitabine IV 30 minute day 1 8 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Arm II : Patients receive epirubicin , cyclophosphamide , paclitaxel arm I . Patients follow every 3 month 6 month , every 6 month 3 year , annually 6 year . PROJECTED ACCRUAL : A total 3,000 patient ( 1,500 per treatment arm ) accrue study within 3-4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose invasive breast cancer Early stage disease Completely resect disease No 8 week since prior resection Any nodal status Indication adjuvant chemotherapy No metastatic disease Hormone receptor status : Estrogen receptor negative weakly positive OR Estrogen receptor positive AND progesterone receptor negative weakly positive PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9 g/dL Hepatic : Bilirubin normal AST ALT great 1.5 time normal Renal : Creatinine great 1.5 time normal Other : Fit receive study chemotherapy No active uncontrolled infection No malignancy within past 10 year except basal cell carcinoma carcinoma situ cervix No concurrent medical psychiatric problem would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
</DOC>